We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| MGC Pharmaceuticals Ltd | ASX:MXC | Australian Stock Exchange | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 0.395 | 0.395 | 0.42 | 0.00 | 01:00:00 |
From Jun 2022 to Jun 2024
By Kyle Morris
Shares in MGC Pharmaceuticals Ltd. rose 13% in early trade Tuesday after the company said that it has completed the preclinical rodent studies on CimetrA, an important step ahead of submission to the U.S. Food and Drug Administration for Investigational New Drug approval.
The pharmaceutical company said that CimetrA is its proprietary investigational medicinal product which has demonstrated anti-inflammatory and immunomodulating properties.
Shares at 0820 GMT were up 0.08 pence at 0.65 pence.
Write to Kyle Morris at kyle.morris@dowjones.com
(END) Dow Jones Newswires
January 10, 2023 03:45 ET (08:45 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year MGC Pharmaceuticals Chart |
1 Month MGC Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
